Antiarrhythmic agents: Drug interactions of clinical significance

Drug Safety

Volumn 23, Issue 6, 2000, Pages 509-532

  Trujillo, T C ^a   Nolan, P E ^b,c  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CISAPRIDE; CODEINE; CYTOCHROME P450; DIGOXIN; DISOPYRAMIDE; FLECAINIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; LIDOCAINE; MEXILETINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMETHOPRIM; UNINDEXED DRUG; WARFARIN;

CIGARETTE SMOKING; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; GENETIC VARIABILITY; HEART ARRHYTHMIA; HUMAN; KIDNEY TUBULE EXCRETION; PRIORITY JOURNAL; REVIEW;

EID: 0034530765     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023060-00003     Document Type: Review

References (233)

1. Mortality and morbidity in patients receiving encainide, flecainide or placebo - The Cardiac Arrhythmia Suppression Trial
2. Junctional tachycardia the role of catheter ablation
3. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
4. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
5. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association
6. Atrial arrhythmias after cardiothoracic surgery
7. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery
8. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy
9. Amiodarone: The expanding antiarrhythmic role how to follow a patient on chronic therapy
10. Pharmacokinetics: The dynamics of drug absorption, distribution and elimination
11. Combination therapy for cardiac arrhythmias
12. Mexiletine in the treatment of resistant ventricular arrhythmias: Enhancement of efficacy and reduction of dose-related side effects by combination with quinidine
13. Rhythm management in atrial fibrillation - With a primary emphasis on pharmacological therapy: Part 1
14. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers and inhibitors
15. Update clinically significant cytochrome P-450 drug interactions
16. Recent advances the cytochrome P450 enzymes
17. Genetically determined adverse drug reactions involving metabolism
18. Genetically determined drug interactions of antiarrhythmic drugs
19. A classification of antiarrhythmic actions reassessed after a decade of new drugs
20. The Sicilian gambit: A new approach to classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms
21. β-Blockers. Drug inter-actions of clinical significance
22. Calcium antagonists. Drug interactions of clinical significance
23. Cardiac glycosides. Drug Interactions of clinical significance
24. Drug interactions with amiodarone
25. Dangerous interaction between amiodarone quinidine
26. Effect of amiodarone on serum quinidine procainamide levels
27. Concurrent use of quinidine disopyramide: Evaluation of serum concentrations electrocardiographic effects
28. The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers
29. Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine
30. Increased procainamide plasma concentrations caused by quinidine: A new drug inter-action
31. Efficacy of propafenone when used in combination with procainamide or quinidine
32. Genetically determined interaction between propafenone low dose quinidine: Role of active metabolites in modulating net drug effect
33. Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects
34. Possible pharmacokinetic interaction with quinidine ciprofloxacin or metronidazole?
35. Possible inhibition of hepatic metabolism of quinidine by erythromycin
36. QT prolongation development of torsades de pointes with the concomitant administration of oral erythromycin base quinidine
37. Itraconazole increases plasma concentrations of quinidine
38. Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy
39. Nifedipine-induced alterations in serum quinidine concentrations
40. Quinidine-nifedipine interaction
41. Nifedipine-quinidine interaction
42. Elucidation of the nifedipine-quinidine interaction
43. Influence of quinidine on nifedipine plasma pharmacokinetics
44. Differential effects of quinidine on the disposition of nifedipine, sparteine and mephenytoin in humans
45. Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine
46. Quinidine interaction with nifedipine and felodipine: Pharmacokinetic and pharmacodynamic evaluation
47. Hypotension after quinidine plus verapamil: Possible additive competition at alphaadrenergic receptors
48. The effect of verapamil on quinidine pharmacokinetics in man
49. Increased quinidine plasma concentrations during administration of Verapramil: A new quinidine-verapramil interaction
50. The effect of coadministration of verapramil on the pharmacokinetics and metabolism of quinidine
51. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine
52. Quinidine-diltiazem: Pharmacokinetic interaction in humans
53. Interaction of quinidine with anticonvulsant drugs
54. Phenytoin-quinidine interactions in a patient with recurrent ventricular tachyarrhythmias
55. Quinidine-rifampin interaction
56. The influence of rifampin on quinidine and digoxin
57. Brown Quinidine-rifampin interaction
58. Apparent quinidine-induced digoxin toxicity after withdrawal of pentobarbital: A case of sequential drug interactions
59. Quinidine interaction with anticonvulsants
60. Anesthesia for atrial fibrillation. Effect of quinidine on muscle relaxation
61. Myasthenia gravis unmasked by antiarrhythmic agents
62. Lack of effect of cimetidine on the metabolism of quinidine: Effect on renal clearance
63. Effect of cimetidine on the pharmacokinetics of quinidine and lidocaine in the rat
64. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine
65. Cimetidine-quinidine interaction
66. Effect of cimetidine on quinidine clearance
67. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine
68. The effect of quinidine on the analgesic effect of codeine
69. Dextromethorphan enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6
70. The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin: A prospective study
71. Characteristics of the digoxin-quinidine digoxin-verapramil interactions in the rat kidney
72. Quinidine and digoxin: An important interaction
73. The quinidine-digoxin interaction in perspective
74. An electrophysiologic study of the quinidine-digoxin interaction
75. Inhibition of the intestinal digoxin absorption and exsorption of quinidine
76. Quinidine reduces clearance of (+) propranolol more than (-) propranolol through marked reduction in 4-hydroxylation
77. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers
78. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol
79. Kinetic evaluation of the propranolol-quinidine combination
80. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate
81. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine
82. Inhibition of desipramine 2-hydroxylation by quinidine and quinine
83. Effect of fluvoxamine on the pharmacokinetics of quinidine
84. Possible quinidine induced hemorrhage in a patient with warfarin sodium
85. Evidence that disopyramide does not interact with warfarin
86. Quinidine-induced hypoprothrombinemic hemorrhage in patients with chronic warfarin therapy
87. Quinidine excretion in aciduria and alkaluria
88. The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: An approach to control quinidine-induced diarrhea
89. Effect of aluminum hydroxide gel on quinidine gluconate absorption
90. Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide
91. Effect of amiodarone on serum quinidine procainamide levels
92. Trimethoprim alters the disposition of procainamide N-acetylprocainamide
93. Trimethoprim inhibition of the renal clearance of procainamide N-acetylprocainamide
94. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide
95. Metoprolol or propranolol does not alter the kinetics of procainamide
96. Cimetidine inhibits renal procainamide clearance
97. Procainamide-cimetidine drug interaction in elderly male patients
98. Interaction of steady-state procainamide with H2-receptor antagonists cimetidine and ranitidine
99. Effect of ranitidine on procainamide disposition
100. Ranitidine and procainamide absorption
101. Ranitidine-induced changes in the renal and hepatic clearances of procainamide are correlated
102. Disopyramide-pyridostigmine: Report of a beneficial drug interaction
103. Randomised placebo controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction
104. Interaction between disopyramide and practolol
105. Atenolol inhibits the elimination of disopyramide
106. The effect of enzyme induction on the metabolism of disopyramide in man
107. Enzyme induction: Rifampin-disopyramide interaction
108. Enhanced metabolism diminished efficacy of disopyramide by enzyme induction
109. Disopyramide and phenytoin interaction
110. Disopyramide pharmacokinetics and metabolism effects of inducers
111. Potentially fatal interaction between erythromycin and disopyramide
112. Hypoglycemia induced by interaction between clarithromycin and disopyramide
113. Comparison of the effects of cimetidine ranitidine on the pharmacokinetics of disopyramide in man
114. Effect of amiodarone on the pharmacokinetics of phenytoin, quinidine, and lidocaine in the rat
115. Amiodarone interaction with lidocaine
116. Reduction in lidocaine clearance during continuous infusion by coadministration of propranolol
117. Altered hepatic blood flow drug disposition
118. The impairment of lignocaine clearance by propranolol - Major contribution from enzyme inhibition
119. Lidocaine elimination: Effects of metoprolol of propranolol
120. Medical treatment of portal hypertension
121. Effects of the α-/βblocking agent carvedilol on hepatic systemic hemodynamics in patients with cirrhosis and portal hypertension
122. Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man
123. Increased toxicity reduced clearance of lidocaine by cimetidine
124. The effect of oral cimetidine on total unbound serum lidocaine concentration in patients with suspected myocardial infarction
125. Effect of duration of lidocaine infusion and route of cimetidine administration on lidocaine pharmacokinetics
126. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes
127. Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients
128. Neuromuscular drug interactions of clinical importance
129. Lidocaine modifies the effect of succinylcholine on muscle oxygen consumption in dogs
130. Effect of rifampicin treatment on the kinetics of mexiletine
131. Enhanced metabolism of mexiletine after phenytoin administration
132. Oral mexiletine-theophylline interaction
133. Proarrhythmia related to a kinetic dynamic interaction of mexiletine and theophylline
134. Mexiletine-theophylline interaction
135. Interaction between theophylline mexiletine
136. Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers
137. Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers
138. Mexiletine effects on theophylline disposition
139. Mechanism of interaction between theophylline mexiletine
140. Newer antidepressants and the cytochrome P450 system
141. Influence of amiodarone on genetically determined drug metabolism in humans
142. Variable disposition kinetics electrocardiographic effects of flecainide during repeat dosing in humans: Contribution of genetic factors dose-dependent clearance, interaction with amiodarone
143. Altered pharmacokinetics of oral flecainide by cimetidine
144. Identification of drug interactions by meta-analysis of pre-marketing trials: The effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate
145. Oral digoxin pharmacokinetics during multiple-dose flecainide treatment
146. Interaction of flecainide with digoxin propranolol
147. The effect of flecainide acetate, a new antiarrhythmic, on plasma digoxin level
148. The influence of urinary pH on flecainide excretion and its serum pharmacokinetics
149. Flecainide pharmacokinetics in healthy volunteers the influence of urinary pH
150. Interaction between propranolol propafenone in healthy volunteers
151. Ciclosporin-propafenone
152. Altered pharmacokinetics of oral flecainide by cimetidine
153. Digoxin-propafenone interactions: Values limitations of plasma determination of the two drugs Antiarrhythmic effectiveness of propafenone
154. Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects
155. Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect
156. Consequences of rifampicin treatment on propafenone disposition in extensive poor metabolizers of CYP2D6
157. Theophylline toxicity after propafenone treatment evidence for drug interaction
158. Propafenone-theophylline interaction
159. Interaction between warfarin and propafenone in healthy volunteer subjects
160. Interaction between sotalol and an antacid preparation
161. Pharmacokinetic drug interactions with amiodarone
162. Drug Interactions with amiodarone
163. Sinus arrest hypotension with combined amiodarone-diltiazem therapy
164. Amiodarone-cyclosporine interaction in cardiac transplantation
165. Amiodaronecyclosporine interaction in a heart transplant patient
166. Cyclosporineamiodarone interaction
167. Amiodarone increases plasma digoxin concentrations
168. Digoxin-amiodarone: A further example of digoxin-antiarrhythmic agents interaction
169. Amiodarone-digoxin interaction, clinical and experimental observations
170. Amiodarone-digoxin interaction: Clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications
171. Pharmacokinetic evaluation of the digoxin-amiodarone interaction
172. Changes in the plasma levels and basic pharmacokinetic parameters of digoxin used in combination with gentamicin, amiodarone and spironolactone
173. Anaesthesia and amiodarone
174. Amiodarone-induced sinus arrest successfully treated with ephedrine and isoproterenol
175. Anesthetic management of the patient receiving amiodarone
176. Pharmacokinetics interaction between intravenous phenytoin amiodarone in healthy volunteers
177. Steady-state interaction between amiodarone and phenytoin in normal subjects
178. Relationship between phenytoin tolbutamide hydroxylations in human liver microsomes
179. Effect of phenytoin on the clinical pharmacokinetics of amiodarone
180. Possible theophyllineamiodarone interaction
181. The mechanism of the interaction between amiodarone warfarin in humans
182. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans
183. Mechanism of warfarin potentiation by amiodarone: Dose- and concentration-dependent inhibition of warfarin elimination
184. Interaction between warfarin Sodium amiodarone
185. The incidence, magnitude, and time course of the amiodarone warfarin interaction
186. Ibutilide: A new class antiarrhythmic agent
187. Dofetilide, a new class III antiarrhythmic agent
188. Adenosine: Supplementary considerations about activity and use
189. Effects of verapramil, propranolol and procainamide on adenosine-induced negative dromotropism
190. Cardiovascular effects of adenosine infusion in man their modulation by dipyridamole
191. Intravenous adenosine in the treatment of supraventricular tachycardia: A dose-ranging study interaction with dipyridamole
192. Cardiovascular effects of infused adenosine in man: Potentiation by dipyridamole
193. Oral dipyridamole increases plasma adenosine levels in human beings
194. Contrasting effects of two xanthines, theophylline and enprofylline on the cardio-respiratory stimulation of infused adenosine in man
195. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans
196. Caffeine and theophylline as adenosine receptor antagonists in humans
197. Subclassification of Class I antiarrhythmic drugs enhanced relevance after CAST
198. Quinidine
199. Electrophysiologic effects clinical efficacy of mexiletine used alone or in combination with Class IA agents for refractory recurrent ventricular tachycardias or ventricular fibrillation
200. Low dose quinidine-mexiletine combination therapy versus quinidine monotherapy for treatment of ventricular arrhythmias
201. Efficacy of combination therapy with mexiletine a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease
202. Usefulness of oral quinidine-mexiletine combination therapy for sustained ventricular tachyarrhythmias as assessed by programmed electrical stimulation when quinidine monotherapy has failed
203. Effect of oral combination therapy with mexiletine and quinidine on left and right ventricular function
204. Combination of disopyramide mexiletine for better tolerance additive effects for treatment of ventricular arrhythmias
205. Intolerance ineffectiveness of mexiletine in patients with serious ventricular arrhythmias
206. The role of combination therapy with mexiletine and procainamide in patients with inducible sustained ventricular tachycardia refractory to intravenous procainamide
207. Electrophysiologic effects and predictors of success of combination therapy with class Ia and 1b antiarrhythmic drugs for sustained ventricular arrhythmias
208. Comparison of class Ia/Ib versus Class antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease
209. Antiarrhythmic drugs devices for the management of ventricular tachyarrhythmia in ischemic heart disease
210. Role of combination drug therapy with a Class IC antiarrhythmic agent and mexiletine for ventricular tachycardia
211. Propafenonemexiletine combination for the treatment of sustained ventricular tachycardia
212. Modulation of antiarrhythmic drug effects by beta-adrenergic sympathetic stimulation
213. Effectiveness of propranolol added to a Type I antiarrhythmic agent for sustained ventricular tachycardia secondary to coronary artery disease
214. Adjuvant metoprolol improves efficacy of class I antiarrhythmic drugs in patients with inducible sustained monomorphic ventricular tachycardia
215. Reversal of proarrhythmic effects of flecainide acetate encainide hydrochloride by propranolol
216. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial
217. Sotalol for ventricular tachyarrhythmias: Beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure
218. Synergy between amiodarone β-blockers after myocardial infarction
219. β-Adrenoceptor blockers in atrial fibrillation the importance of partial agonist activity
220. Xamoterol improves the control of chronic atrial fibrillation in elderly patients
221. Crijns HJGM. Current treatment recommendations in antiarrhythmic therapy
222. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision
223. A prospective comparison of Class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible sustained ventricular tachycardia
224. Efficacy and safety of combination therapy with amiodarone and Type I agents for treatment of inducible ventricular tachycardia
225. The amiodarone-class 1 agent combination increases refractoriness, conduction, and the number of electrophysiologic studies. But does it increase survival rate?
226. Flecainide and amiodarone combined therapy for refractory tachyarrhythinias in infancy
227. Sotalol type 1A drugs in combination prevent recurrences of sustained ventricular tachycardia
228. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: Elimination of reverse use dependence
229. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up
230. Importance of beta blockade in the therapy of serious ventricular arrhythmias
231. Sudden cardiac death
232. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience